CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease

This policy describes coverage stance for laboratory tests used to diagnose or monitor inflammatory bowel disease (Crohn's disease and ulcerative colitis) for Blue Cross Blue Shield - Tennessee members, including serologic, genetic, and panel-based tests.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyLaboratory Testing for the Diagnosis of Inflammatory Bowel Disease

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionVerify member benefits before ordering; serologic panels, genetic testing, and Prometheus-style algorithmic tests do not meet coverage criteria and may be denied.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>200distinct susceptibility genetic loci discussed

17biomarkers in common diagnostic panels

meta-analysisevidence for ASCA/pANCA

high-complexityLDT regulatory class

Coverage Criteria — Tests for IBD

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Not Medically Necessary / Not Covered

The following tests do not meet coverage criteria for the workup, diagnosis, or monitoring of IBD:

Serologic markers not covered: Use of serologic markers (including but not limited to ANCA, ASCA, pANCA, anti-OmpC, anti-I2, anti-cBir1, ACCA IgA, ALCA IgG, AMCA IgG, PKM2) for the workup and monitoring of IBD does not meet coverage criteria.

See policy statements listing specific serologic analytes.

Diagnostic algorithm/panel testing not covered: Diagnostic algorithm–based testing that combines serologic, genetic, and inflammation markers (for example, Prometheus® combined panels) does not meet coverage criteria.

Policy explicitly names Prometheus-style combinatorial testing as not meeting coverage criteria.

Genetic testing not covered: Genetic testing for IBD does not meet coverage criteria for routine diagnosis, workup, or monitoring.

Policy states genetic testing for IBD DOES NOT MEET COVERAGE CRITERIA.

inv-02: Coverage criteria by clinical scenario

Guideline-derived coverage stance for serologic/genetic testing in IBD:

Routine diagnosis in adults: Genetic testing and routine serologic antibody testing (eg, ASCA, pANCA) are not indicated to establish the diagnosis of Crohn's disease or ulcerative colitis and are not recommended for routine clinical practice.

Supported by AGA, ACG, ACG UC guidance, ECCO/E ESGAR statements.

Use to differentiate IBS vs IBD or unclear cases: Serologic markers (ASCA, pANCA) may be used to support differential diagnosis between IBS and IBD or when noninvasive testing (eg, fecal calprotectin) is equivocal; however, these markers have limited sensitivity and modest incremental diagnostic value, and fecal biomarkers/CRP are generally favored to rule out IBD in IBS presentations.

References: Nakov review, ACG IBS guidance, WGO, BSG/ECCO statements.

Pediatric and VEO-IBD / genetic testing: Genetic sequencing (targeted panels, WES, WGS) is indicated in very early‑onset IBD (<6 years) or when phenotype, family history, consanguinity, abnormal immunologic studies, recurrent infections, HLH, or refractory/unusual IBD suggests a monogenic disorder; perform targeted panels first, then WES if panels are negative, with WGS reserved for select cases per NASPGHAN guidance.

NASPGHAN guidance recommends targeted panels first and selective use of WES/WGS.

Serologic antibody tests, algorithm-based diagnostic panels that combine serologic, genetic, and inflammatory markers, and genetic testing have all been evaluated as adjuncts in the assessment of inflammatory bowel disease (IBD). However, this policy finds that these modalities DOES NOT MEET COVERAGE CRITERIA for routine workup, diagnosis, or monitoring of IBD because available published scientific literature does not demonstrate they are required and beneficial for patient management. Examples called out in the policy include serologic markers such as ANCA and ASCA, algorithm-based panels (e.g., Prometheus-style combined testing), and genetic testing for IBD.

Clinical practice guidelines from major societies recommend that genetic testing and routine serologic antibody testing (eg, ASCA, pANCA) should not be used to establish or routinely classify Crohn's disease or ulcerative colitis in adults. These guidance statements emphasize that diagnosis is based on integration of clinical, endoscopic, radiologic, and histologic findings and that genetic or serological markers are not indicated for routine diagnostic classification in adult patients.

Many laboratory-developed tests (LDTs) used for serologic or genetic IBD testing are validated and performed in-house and are regulated as high-complexity tests under CLIA '88. Such LDTs are not approved or cleared by the U.S. Food and Drug Administration; however, FDA clearance or approval is not required for clinical use. Laboratories performing LDTs must follow CLIA requirements for validation and high‑complexity testing.

Commercial multi-analyte panels (for example Prometheus IBDsgi and related Prometheus products) have been studied for discriminating IBD subtypes and for prognostic purposes. While some studies reported improved discrimination when combining serologic, genetic, and inflammatory markers, independent commentary has raised concerns about the incremental predictive value of these panels; for example, analyses suggest much of the Prometheus IBDsgi diagnostic performance may be attributable to a small subset of widely available components rather than the full commercial algorithm.

Use of the following serologic markers, algorithm-based panels, and genetic tests DOES NOT MEET COVERAGE CRITERIA for the workup, diagnosis, or monitoring of IBD: ANCA, ASCA, pANCA, anti‑OmpC, anti‑I2, anti‑cBir1, ACCA (IgA), ALCA (IgG), AMCA (IgG), PKM2, diagnostic algorithm–based testing that combines serologic/genetic/inflammatory markers (eg, Prometheus® testing), and genetic testing for IBD.

Routine use of serologic antibody testing or genetic testing for diagnosis or prognosis of adult Crohn's disease or ulcerative colitis is not supported by guideline recommendations and is considered not medically necessary for routine clinical practice. Serologic markers may have limited adjunctive value in specific, equivocal clinical scenarios, but they are not recommended as routine diagnostic or prognostic tools in adults.

Covered Indications and Appropriate Uses

inv-38: Fecal calprotectin, ESR, and CRP

Covered when used to assess inflammation, correlate with disease activity, or to help distinguish IBD from noninflammatory conditions:

Inflammation markers for activity and monitoring: Fecal calprotectin, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) are useful for correlating with disease activity and monitoring response to treatment in patients with suspected or known IBD.

Fecal calprotectin is specifically noted as useful to differentiate IBD from IBS and for monitoring; see referenced fecal calprotectin policy.

Role in diagnostic workup: When integrated with clinical, endoscopic, imaging, and histologic findings, inflammatory markers (including fecal calprotectin and CRP) contribute to assessment of disease activity and may aid diagnostic evaluation.

Guidelines and evidence syntheses discuss these biomarkers as complementary to other diagnostic modalities.

inv-39: Supportive testing to help differentiate CD vs UC or organic IBD vs IBS when noninvasive tests are inconclusive or small-bowel evaluation is being considered.

Supportive serologic testing may be considered in selected situations as an adjunct to clinical assessment:

Differentiate Crohn's vs Ulcerative Colitis: ASCA positivity increases the likelihood of Crohn's disease and pANCA positivity increases the likelihood of ulcerative colitis, but both assays have limited sensitivity; serologic testing has higher specificity than sensitivity and therefore may help when other evaluations are inconclusive.

Meta-analysis and cohort studies show ASCA+/pANCA- has moderate sensitivity and high specificity; tests may be more informative in pediatric populations.

Use when noninvasive tests inconclusive or planning small‑bowel evaluation: Serologic markers may add value when noninvasive tests (eg, fecal calprotectin) are equivocal or when contemplating advanced small‑bowel evaluation (eg, capsule endoscopy), but should not replace definitive imaging or endoscopy.

WGO and other guidance note potential added value when considering advanced small‑bowel assessment.

inv-40: Genetic testing for suspected monogenic VEO-IBD or unusual/refractory pediatric presentations — targeted panels first; WES/WGS per NASPGHAN guidance.

Genetic testing is covered when clinical features suggest a monogenic etiology in pediatric patients:

Indications for genetic testing: Genetic sequencing (targeted panels, WES, WGS) is indicated in suspected monogenic very early‑onset IBD (VEO‑IBD, onset <6 years) or in pediatric patients with phenotype, family history, consanguinity, abnormal immunologic studies, recurrent severe infections, hemophagocytic lymphohistiocytosis (HLH), or refractory/unusual disease suggesting monogenic causes.

NASPGHAN guidance supports sequencing in VEO‑IBD and describes when to use targeted panels versus WES/WGS.

Testing strategy: Perform targeted gene panels first when phenotype suggests a known defect; if targeted panels are negative and suspicion remains high, proceed to whole‑exome sequencing (WES); reserve whole‑genome sequencing (WGS) for select cases per specialist guidance.

NASPGHAN recommends targeted panels first, WES when panels negative, and selective WGS use.

Clinical utility: Although many susceptibility loci for IBD have been identified, most confer small increments in risk and current genetic testing has limited utility for routine adult diagnosis; genetic testing has higher yield and actionable implications in monogenic pediatric presentations.

inv-41: Diagnosis, differentiation, and monitoring of IBD using serologic markers and other biomarkers — evidence and guidelines cited.

Serologic markers and other biomarkers have a defined but limited role in IBD assessment according to evidence and guideline sources:

Complementary diagnostic/monitoring role: Serologic markers and other biomarkers may contribute to diagnosis, differentiation, and monitoring of IBD when used as part of an integrated clinical assessment, but they are not standalone diagnostic tests and have variable sensitivity and specificity across studies.

Multiple evidence‑based references and society guidelines discuss biomarker roles and limitations.

Limitations and guideline recommendations: Multiple guidelines and systematic reviews caution against routine use of serologic or genetic markers for diagnosis or prognosis in adults; biomarkers should be applied selectively and in context of clinical, endoscopic, radiologic, and histologic data.

Guidelines from ACG, ECCO, AGA and others report limited utility for routine serologic/genetic testing.

inv-42: Diagnostic evaluation to differentiate Crohn's disease, ulcerative colitis, and non-IBD when used as part of clinical assessment — supported by cited studies.

Supported as part of a comprehensive diagnostic evaluation when used adjunctively with clinical, endoscopic, imaging, and histologic data:

Adjunctive diagnostic evaluation: Serologic panels and biomarker testing may be used to assist differentiation between Crohn's disease, ulcerative colitis, and non‑IBD when interpreted within the full clinical assessment, but routine standalone use for classification or prognostication in adults is not supported.

Diagnostic accuracy studies and guideline references support adjunctive but limited use.

Interpretation and integration: Results of serologic and biomarker testing should be integrated with endoscopic, histologic, and cross‑sectional imaging findings; positive serology may increase likelihood of a diagnosis (eg, ASCA for CD) but does not replace definitive diagnostic procedures.

References include Prometheus studies and multiple diagnostic accuracy publications; policy emphasizes integration with other diagnostic modalities.

Not Covered Tests and Panels

The following serologic markers and diagnostic algorithm-based panels are listed as not meeting coverage criteria for IBD evaluation: ANCA, ASCA, pANCA, anti‑OmpC, anti‑I2, anti‑cBir1, ACCA IgA, ALCA IgG, AMCA IgG, PKM2, and diagnostic algorithm/panel tests that combine serologic, genetic, and inflammatory markers (for example, Prometheus® testing). Genetic testing for IBD is also listed as not meeting coverage criteria.

Routine serologic antibody testing or genetic testing for the diagnosis or prognosis of adult Crohn's disease or ulcerative colitis is not recommended by major society guidance and therefore is not supported for routine coverage in adults. Guidelines note low sensitivity for many serologic markers and only modest yield for predicting disease course, supporting the policy position against routine use.

Some sections of the source do not explicitly enumerate additional tests as 'not covered' beyond the lists already provided. The document also notes regulatory context for laboratory‑developed tests: LDTs are regulated under CLIA as high‑complexity tests and are not FDA‑cleared or approved for clinical use, though FDA clearance is not required for their clinical application.

Although not all excerpts explicitly name further ‘not covered’ tests, the policy and cited literature comment on limited incremental value of some commercial panels. Specifically, critique in the literature has suggested that the predictive performance of Prometheus IBDsgi may derive largely from a limited subset of its component markers rather than the full commercial algorithm, raising concerns about the added clinical value of the complete panel.

Provider Actions, Prior Authorization, and Practical Notes

Documentation Required

Benefit Verification and Regulatory Precedence

If there is a conflict between this policy and any applicable government policy (e.g., LCDs, NCDs for Medicare or state Medicaid rules), the government policy governs the determination. Verify member benefits before ordering; coverage may vary by benefit plan and by Medicare/Medicaid rules.

Benefit verification required — coverage depends on individual benefits; Medicare/Medicaid specifics referenced.
Regulatory precedence: government policy (LCD/NCD/state) supersedes this payer policy in case of conflict.

Documentation Required

Laboratory Validation and Compliance Requirements

Laboratory-developed tests (LDTs) must be validated and performed in CLIA '88 high-complexity certified laboratories. LDTs are not FDA-approved/cleared for clinical use but are regulated under CLIA; failure to use validated, CLIA-compliant tests may risk non-compliance and potential denial of coverage.

LDT validation and CLIA compliance required — labs must validate LDTs and meet CLIA high-complexity requirements.
Regulatory non-compliance risk — use of non-validated LDTs may lead to denial.

Note

Adoption of Avalon Policy Recommendations

Adopted Avalon policy recommendations are in effect as of the effective date. Tests and panels inconsistent with the adopted Avalon recommendations may be denied or subject to reimbursement rules per this policy.

Adoption of external (Avalon) policy — effective 7/1/2023.
Tests inconsistent with adopted Avalon recommendations could be denied under reimbursement rules.

Note

Citations and Guideline References

The policy cites multiple clinical guidelines and literature sources to support coverage determinations. Providers should reference these clinical guideline sources when documenting medical necessity or contesting coverage decisions.

Citations and clinical guideline references provided — ACG, AGA, NICE, Prometheus literature, and peer-reviewed studies.
Use cited guidelines (e.g., ACG, AGA) to support clinical rationale; note that ACG states genetic testing is not indicated to establish Crohn's diagnosis.

Step Therapy

No step therapy requirements are specified for serologic or genetic testing in this policy. There are no step-therapy or quantity-limit constraints described for these tests within the referenced sections.

No step therapy requirements are specified for serologic/genetic testing in these sections.

Denial Risk

Denial Risk — Tests That Do Not Meet Coverage Criteria

The following tests and panels DO NOT MEET COVERAGE CRITERIA for workup or monitoring of IBD: listed serologic markers (ANCA, ASCA, pANCA, anti-OmpC, anti-I2, anti-CBir1, ACCA IgA, ALCA IgG, AMCA IgG, PKM2), diagnostic algorithm-based testing (e.g., Prometheus panels), and genetic testing for IBD. Providers should document alternative clinically accepted testing (e.g., fecal calprotectin, ESR, CRP) when relevant.

Serologic markers listed are not covered for routine IBD workup or monitoring.
Diagnostic algorithm-based testing (including Prometheus®) does not meet coverage criteria.
Genetic testing for IBD does not meet coverage criteria.

Ordering and Specialist Referral Requirements

Billing Rule

Ordering requirements — verify benefits

Verify member benefits prior to ordering; no clinician-type ordering restriction is specified in these excerpts.

Coverage depends on individual benefit coverage at time of request.
The policy excerpt does not impose a restriction on which clinician may order testing.

Documentation Required

Ordering requirements — specialist involvement for VEO-IBD genetic testing

Genetic testing for very early-onset IBD (VEO-IBD) should be ordered by, or in consultation with, specialists experienced in pediatric IBD/genetics as described in NASPGHAN guidance.

NASPGHAN recommends targeted panels first for infantile-onset or phenotype-consistent cases and WES/WGS per specified indications.
Specialist involvement is implied by guideline recommendations for genetic sequencing in VEO-IBD.

Note

Ordering requirements — no explicit provider restrictions

These excerpts do not state explicit ordering-provider restrictions for serologic, algorithm-based, or genetic testing.

No explicit restrictions on which clinician may order these tests are provided in the referenced sections.

Note

Ordering requirements — no specific clinician requirements

No specific ordering clinician requirements are provided in these policy excerpts for the tests discussed.

Guidelines and literature are cited, but the policy does not impose clinician-type ordering rules in the provided sections.

Definitions and Abbreviations

Ulcerative colitis

DefinitionChronic inflammatory condition limited to the mucosal layer of the colon with relapsing and remitting inflammation beginning at the rectum and extending proximally in a continuous fashion.

Typical featuresMucosal inflammation confined to colon; presents with rectal bleeding, diarrhea, and urgency.

Relation to IBDOne of the two major forms of IBD alongside Crohn's disease.

Crohn's disease

DefinitionInflammatory bowel disease characterized by patchy transmural inflammation (skip lesions) of the gastrointestinal tract, which can produce sinus tracts, microperforations, fistulae, fibrosis, and strictures.

Typical featuresTransmural inflammation, skip lesions, potential for fistulae and stricturing disease presentations not typical of UC.

Relation to IBDOne of the two major forms of IBD alongside ulcerative colitis.

Selected serologic and biomarker abbreviations

ASCAAnti-Saccharomyces cerevisiae antibody

ANCA / pANCAAnti-neutrophil cytoplasmic antibody; pANCA = perinuclear ANCA

ACCA / ALCA / AMCAACCA = Antichitobioside carbohydrate antibody; ALCA = Antilaminaribioside antibody; AMCA = Antimannobioside antibody

PKM2Pyruvate kinase M2

7C47α-hydroxy-4-cholesten-3-one

ASCA / pANCA

UseASCA and pANCA are serologic antibodies evaluated to support differentiation between Crohn's disease and ulcerative colitis (ASCA more associated with CD; pANCA more associated with UC).

LimitationsBoth markers have limited sensitivity and are not definitive diagnostic tests; used as supportive information only.

Clinical roleMay assist in differential diagnosis or when noninvasive tests are equivocal, but not recommended for routine diagnosis in adults.

VEO-IBD

DefinitionVery Early-Onset Inflammatory Bowel Disease (VEO-IBD) = IBD presenting under 6 years of age.

ImplicationGenetic sequencing is often necessary to identify monogenic forms; targeted gene panels first, with WES/WGS recommended per NASPGHAN guidance when indicated.

Clinical triggers for testingConsider when phenotype is consistent with a known defect, family history, consanguinity, abnormal immunology, refractory/unusual disease course.

Laboratory-developed test (LDT)

DefinitionLaboratory-developed test (LDT) = an in-house diagnostic test developed and validated by a laboratory.

Regulatory noteLDTs are regulated by CMS as high-complexity tests under CLIA '88 and are not approved or cleared by the FDA; FDA clearance is not required for clinical use.

Laboratory responsibilityLDTs must be validated and performed in-house per CLIA high-complexity requirements.

Prometheus IBD sgi Diagnostic

ProductPrometheus IBDsgi Diagnostic = commercial combined serological, genetic, and inflammatory marker panel offered by Prometheus Laboratories.

Related productsPrometheus Monitr Crohn's and PredictrPK IFX are other Prometheus products referenced in the bibliography.

Literature notePrometheus tests are cited in diagnostic studies and commentary within the policy bibliography.

ASCA / pANCA (clarified)

ASCAAnti-Saccharomyces cerevisiae antibodies — higher serum concentrations in Crohn's disease compared with ulcerative colitis; useful as a supportive marker.

pANCAPerinuclear anti-neutrophil cytoplasmic antibodies — more often positive in ulcerative colitis but with low sensitivity; not definitive alone.

Clinical utilityEvaluated in multiple studies and meta-analyses for diagnostic discrimination between IBD subtypes; best used as adjunctive information.

OpenPayer

Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease

Coverage Criteria — Tests for IBD

Covered Indications and Appropriate Uses

Not Covered Tests and Panels

Named Biomarkers and Coding

Provider Actions, Prior Authorization, and Practical Notes

Ordering and Specialist Referral Requirements

Definitions and Abbreviations

Frequency Limits and Testing Intervals

Background and Evidence Summary

Bibliography and Guideline Sources

ASCA	Anti-Saccharomyces cerevisiae antibody
ANCA	Anti-neutrophil cytoplasmic antibody
pANCA	Perinuclear anti-neutrophilic cytoplasmic antibody
anti-OmpC	Antibody to Escherichia coli outer membrane porin C
anti-I2	Antibody to Pseudomonas fluorescens-associated sequence I2
anti-cBir1	Anti-CBir1 flagellin antibody
ACCA IgA	Antichitobioside carbohydrate antibody
ALCA IgG	Antilaminaribioside antibodies
AMCA IgG	Antimannobioside antibodies
PKM2	Pyruvate kinase M2